AMG 160 DATA AT ESMO VIRTUAL CONGRESS 2020

SEPTEMBER 21, 2020



SAFE HARBOR STATEMENT

This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company, including BeiGene, Ltd. or any collaboration or potential collaboration in pursuit of therapeutic antibodies against COVID-19 (including statements regarding such collaboration's, or our own, ability to discover and develop fully-human neutralizing antibodies targeting SARS-CoV-2 or antibodies against targets other than the SARS-CoV-2 receptor binding domain, and/or to produce any such antibodies to potentially prevent or treat COVID-19), or the Otezla® (apremilast) acquisition (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, outcomes, progress, or effects relating to studies of Otezla as a potential treatment for COVID-19, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form &-K. Unless otherwise noted, Amgen is providing this information as of the date of this presentation and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future ev

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure. political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies. products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.



AGENDA

Introduction	David Reese, M.D.—Executive Vice President, Research and Development
AMG 160 Data Overview	Gregory Friberg, M.D.—Vice President, Global Development and Oncology Therapeutic Area Head
Q&A	David Reese, M.D. Gregory Friberg, M.D.



INTRODUCTION

DAVID REESE, M.D. EXECUTIVE VICE PRESIDENT, RESEARCH AND DEVELOPMENT



AMGEN IS THE LEADER IN BITE® IMMUNO-ONCOLOGY



BLINCYTO[®] is the only FDA Approved BiTE[®] Therapy



Most robust pipeline

with 10 investigational molecules across solid tumors and blood cancers



Most Patients Studied

To date, Amgen's BiTE[®] immuno-oncology platform has been investigated in more than 3,000 patients

BiTE® = bispecific T-cell engager



AMGEN'S BITE® PLATFORM: A CLINICALLY VALIDATED IMMUNO-ONCOLOGY THERAPY

- Clinically validated off-the-shelf immuno-oncology therapy
- Seamlessly integrated, scalable, industrialized platform
- Clinical activity demonstrated in both liquid and solid tumors
- Advancing half-life extended BiTE[®] constructs against high-quality targets in prostate cancer, SCLC, MM and gastric cancer
- Applying learnings across programs to optimize dose / schedule and mitigate adverse events
- Exploring strategies to prevent resistance
 - Combinations with PD-1 antibodies are ongoing
 - Additional combinations and rational sequences are planned



AMG 160 UPDATE

GREGORY FRIBERG, M.D.

VICE PRESIDENT, GLOBAL DEVELOPMENT AND ONCOLOGY THERAPEUTIC AREA HEAD



PROSTATE CANCER IS A LEADING CAUSE OF MORTALITY IN MEN

- #1 diagnosed non-cutaneous cancer in men in the U.S. and EU, #2 worldwide¹⁻⁴ •
- ~ 1.3 million new diagnoses and ~ 360,000 estimated deaths due to prostate cancer • worldwide in 2018⁵
- Androgen-deprivation therapy (ADT) is the standard of care for regional or • advanced prostate cancer, however most men progress to castrate resistant prostate cancer (CRPC)^{6,7}
- \sim 1/3 of patients with CRPC develop metastases within two years of diagnosis⁸
- Metastatic CRPC (mCRPC) remains incurable despite current treatments, including • ADT, chemotherapy, immunotherapy, radium isotope and palliative therapies⁹
- The five-year survival rate for mCRPC is 30%, representing a high unmet • medical need²

1. Ferlay J, et al. Eur J Cancer. 2018;103:356-387. 2. SEER Cancer Stat Facts: Prostate Cancer. seer.cancer.gov/ statfacts/html/prost.html. Accessed March 14, 2019. 3. Bray F, et al. CA Cancer J Clin. 2018;68:394-424. 4. Gandaglia G, et al. Prostate. 2014;74:210-216.5. The Global Cancer Observatory. https://aco.jarc.fr/today/data/factsheets/cancers/27-Prostate-fact-sheet.pdf. 6. Crawford ED. et al. Urol Oncol. 2017:355:S1-S13.7. Nouri M. et al. Front Oncol. 2014:4:370. 8. Kirby M. et al. Int J Clin Pract. 2011;65:1180-1192. 9. Sumanasuriya S, et al. Cold Spring Harb Perspect Med. 2018;8:a030635. Provided September 21, 2020, as part of an oral presentation and is 8 qualified by such, contains forward-looking statements, actual results may

vary materially; Amgen disclaims any duty to update.

PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA): A COMPELLING TARGET FOR PROSTATE CANCER

- PSMA is a type II transmembrane glycoprotein highly expressed on the surface of prostate cancer cells
- Considered an independent indicator of poor prognosis¹⁻⁵
 - High expression on biopsy is associated with increased chance of disease recurrence
 - Expression increases with tumor aggressiveness, androgen independence, metastatic disease, and disease recurrence
- Low, predominantly cytoplasmic expression in some normal tissues, including prostate, brain, kidney, liver and small intestine
- Low membrane expression on select tumors: NSCLC, neuroendocrine, breast



^{1.} Chang SS. Rev Urol. 2004;6(suppl 10):S13-S18. 2. Bouchelouche K, et al. Discov Med. 2010;9:55-61. 3. Bravaccini S, et al. Sci Rep. 2018;8:4254. 4. Chang SS, et al. Cancer Res. 1999;59:3192-3198. 5. Hupe MC, et al. Front Oncol. 2018;8:623..

Interim results from a phase 1 study of AMG 160, a halflife extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE[®]) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)


Ben Tran, MBBS, FRACP,¹ Lisa Horvath, PhD, MBBS, FRACP,² Tanya Dorff, MD,³ Matthew Rettig, MD,⁴ Martijn P. Lolkema, MD, PhD,⁵ Jean-Pascal Machiels, MD,⁶ Sylvie Rottey, MD, PhD,⁷ Karen Autio, MD,⁸ Richard Greil, MD,⁹ Nabil Adra, MD, MSc,¹⁰ Charlotte Lemech, MD, FRACP,¹¹ Mukul Minocha, PhD,¹² Fu-Chih Cheng, PhD,¹² Hosein Kouros-Mehr, MD, PhD,¹² Karim Fizazi, MD, PhD¹³

¹Peter MacCallum Cancer Centre, Melbourne, Australia; ²Chris O'Brien Lifehouse, Camperdown, Australia; ³City of Hope, Duarte, CA, USA; ⁴University of California, Los Angeles, CA, USA; ⁵Erasmus MC Cancer Institute, Rotterdam, Netherlands; ⁶Cliniques Universitaires Saint-Luc, Brussels, Belgium; ⁷Drug Research Unit, Ghent University, Ghent, Belgium; ⁸Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁹Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-CCCIT and Cancer Cluster, Salzburg, Austria; ¹⁰Indiana University School of Medicine, Indianapolis, IN, USA; ¹¹Scientia Clinical Research, Randwick, Australia; ¹²Amgen Inc., Thousand Oaks, CA, USA; ¹³Gustave Roussy, University of Paris Saclay, Villejuif, France

Presented at European Society of Medical Oncology 2020 Virtual Congress, September 19-21, 2020



AMGEN BITE[®] (BISPECIFIC T-CELL ENGAGER) IMMUNOTHERAPY




- BiTE[®] molecules engage a patient's own T cells to attack and eradicate cancer cells¹
 - T-cell activation induces transient cytokine release and tumor killing¹
- Blinatumomab (BLINCYTO[®], Amgen Inc.) is the first and only bispecific immunotherapy approved in oncology worldwide¹
- AMG 160 is a half-life extended PSMA x CD3 BiTE[®] immunotherapy for mCRPC

1. Baeuerle PA, et al. Cancer Res. 2009;69:4941-4. 2. Klinger M, et al. Immun Rev. 2016;270(1):193-208. 3. Bargou R, et al. Science. 2008;321:974-7. 4. Stieglmaier J, et al. Expert Opin Biol Ther. 2015;15(8):1093-9.



FIRST-IN-HUMAN DOSE EXPLORATION STUDY OF AMG 160



- Study design Phase 1, global, open-label study evaluating safety and tolerability of AMG 160 monotherapy (Part 1) or in combination with pembrolizumab (Part 2)
- Dosing schedule IV infusion every 2 weeks (after target dose reached)

FIH = first-in-human; IV = intravenous; mCRPC = metastatic castration-resistant prostate cancer; MTD = maximum tolerated dose; PD = pharmacodynamics; PK = pharmacodynamics; RP2D = recommended phase 2 dose



KEY ELIGIBILITY CRITERIA AND DEMOGRAPHICS

- Inclusion Criteria
 - Histologically or cytologically confirmed mCRPC refractory to novel hormonal therapy and
 - Have failed 1–2 taxane regimens; or
 - Patient deemed unsuitable for or has refused taxanes
 - Evidence of progressive disease per PCWG3
- Exclusion Criteria
 - Active autoimmune disease or requiring immunosuppressive therapy
 - Prior PSMA-targeted therapy (patients treated with PSMA radionuclide therapy may be eligible)
 - CNS metastases, leptomeningeal disease, or spinal cord compression

Baseline Demographics	All (N = 43)
Median (range) age, y	66.0 (49–78)
Race, n (%)	
Asian	2 (4.7)
Black	2 (4.7)
White	34 (79.1)
Other	5 (11.6)
Prior lines of therapy, n (%)	
1	2 (4.7)
2	4 (9.3)
3	9 (20.9)
≥ 4	26 (60.5)
Median (range)	4 (1–9)
Median (range) PSA at baseline, μ g/L	79.2 (0.1–4035.0)
RECIST-measurable disease, n (%)	15 (34.9%)

CNS = central nervous system; PCWG3 = Prostate Cancer Clinical Trials Working Group 3; RECIST = Response Evaluation Criteria in Solid Tumors



ADVERSE EVENTS (AES) AND ANTIDRUG ANTIBODIES (ADAS)

- 43 patients received ≥ 1 dose of AMG 160 monotherapy
 - 41 (95.3%) patients experienced TEAEs
 - 19 (44.2%) patients remained on AMG 160 at the time of data analysis
 - 6 (14.0%) received treatment ≥ 6 months

TRAEs

- 41 (95.3%) patients experienced TRAEs
 - No grade 5 events, and none resulted in treatment discontinuation
- 3 reversible dose-limiting toxicities occurred
 - Grade 3 rash (n = 2)
 - Grade 3 GI hemorrhage (n = 1)

ADAs

- 6 of 30 (20.0%) patients assessed developed ADAs affecting drug exposure between cycles 1 and 10
 - No AEs associated with ADAs were observed

TRAEs in $\ge 20\%$ of patients (N = 43)*

TRAE, n (%)	All Grade, n (%)	Grade 3, n (%)
CRS (Lee criteria) [†]	39 (90.7)	11 (25.6)
Fatigue	19 (44.2)	1 (2.3)
Vomiting [†]	19 (44.2)	0 (0)
Nausea [†]	17 (39.5)	0 (0)
Pyrexia [†]	16 (37.2)	0 (0)
Headache [†]	15 (34.9)	0 (0)
Diarrhoea [†]	14 (32.6)	2 (4.7)
Dry mouth	13 (30.2)	0 (0)
Rash [†]	12 (27.9)	4 (9.3)
Hypophosphataemia	11 (25.6)	4 (9.3)
Hypotension ⁺	10 (23.3)	5 (11.6)
Chills [†]	10 (23.3)	0 (0)
Dysgeusia	10 (23.3)	0 (0)
Decreased appetite	9 (20.9)	0 (0)

* 8 patients experienced grade 4 laboratory abnormalities that were clinically non-significant; † CRS-related

20 July 2020 cutoff; ADA = antidrug antibody; AE = adverse event; CRS = cytokine release syndrome; GI = gastrointestinal; TEAE = treatment-emergent adverse event; TRAE = treatment-related adverse event



CHARACTERISTICS OF CYTOKINE RELEASE SYNDROME

- CRS was reversible, manageable, most severe in cycle 1 and associated with fever, hypotension, transient transaminitis, nausea/vomiting and/or diarrhea (Lee 2014 grading)
 - No grade 4/5 CRS events or treatment discontinuations
 - 26 (60.5%) patients had grade 2 CRS as worst grade (hypotension: 15 [34.9%]; transaminitis: 13 [30.2%])*
 - 11 (25.6%) patients had grade 3 CRS as worst grade (hypotension: 6 [14.0%]; transaminitis: 10 [23.3%])*
 - Transaminitis events were short-term AST/ALT elevations not associated with long-term hepatic dysfunction
 - 4 (9.3%) patients experienced reversible atrial fibrillation in setting of CRS/tachycardia

CRS Grading (Lee 2014)			
Grade 1	Grade 2	Grade 3	Grade 4 [†]
Fever, nausea, fatigue, etc, requiring symptomatic treatment only	 Grade 1 CRS symptoms and O₂ requirement < 40% Intravenous fluids or low-dose vasopressor for hypotension Grade 3 transaminitis 	 Grade 1 CRS symptoms and O₂ requirement ≥ 40% High-dose or multiple vasopressors for hypotension Grade 4 transaminitis 	 Grade 1 CRS symptoms and Requirement for ventilator Grade 4 organ toxicity (excluding transaminitis)

* Data from investigators, database-reported AEs, and laboratories (20 July 2020); [†] No grade 4 CRS events were observed at the time of data cutoff (20 July 2020) AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CRS = cytokine release syndrome Provided September 21, 2020, as part of an oral presentation and is

AMGEN°

qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

15

PROPHYLACTIC MITIGATIONS TO IMPROVE CRS PROFILE

Prophylactic Mitigations in Cycle 1 Priming Cohort			
Dose priming	Dexamethason	e premedication	Prophylactic IV hydration
Lower run-in dose before maintenance target dose	•	8 mg IV before 60 dose*	1L normal saline after AMG 160 dose
Safety Outcomes With Prophylactic Mitigation Strategy			
Cohort 5 (unoptimised),	0.3 mg (n = 4)	Cohort 5 (optimi	sed), 0.3 mg (n = 5)
No DLTs		No DLTs	
 SAEs, (n = 4; including 	g 3 CRS events)	No SAEs	
 Grade 2 CRS (n = 3) 		Grade 2 CRS	(n = 3)
 Grade 3 CRS (n = 2) 		No Grade 3 Cl	RS



AMG 160 DEMONSTRATES EFFICACY WITH LONG-TERM RESPONSES

PSA/CTC Responses (n = 13–35)		
Response	All, n (%)	
PSA response, confirmed*	8 (27.6)	
PSA response, unconfirmed [†]	4 (11.4)	
CTC0 response [‡]	3 (23.1)	


RECIST Responses (n = 15)		
Response	All, n (%)	
Partial response, confirmed	2§ (13.3)	
Partial response, unconfirmed	1§ (6.7)	
Stable disease	8 (53.3)	

* ≥ 30% reduction based on 29 patients with 2 postbaseline PSA results

[†] ≥ 30% reduction based on 35 patients with measurable PSA at baseline

[‡]Based on 13 patients with baseline CTC > 0 and postbaseline CTC assessment

§1 PR(u) and 1 PR confirmation occurred after 20 July 2020



CTC = circulating tumor cell; DLT = dose-limiting toxicities; NE = not evaluable; PSA = prostate-specific antigen; PR = partial response; Q2W = every 2 weeks; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease; (u) = unconfirmed


* PR occurred before but reported after 20 July 2020 data cutoff; PR (u) reported after 20 July 2020 data cutoff

[†]Checkered bars indicate cohorts with optimised cycle 1 priming strategies



PSA REDUCTIONS IN THE MAJORITY OF EVALUABLE PATIENTS*

- PSA reductions (best response) were dose dependent and occurred in 24/35 (68.6%) evaluable patients (20 July 2020)
- PSA reductions > 50% occurred in 12/35 (34.3%) evaluable patients



PSA50 = PSA decrease of ≥ 50%; Q2W = every 2 weeks; * Best PSA reductions at any time point in evaluable patients included those who had received ≥ 1 dose of AMG 160 and had measurable baseline PSA; † Checkered bars indicate cohorts with optimised cycle 1 priming strategies; ▲ Indicates patient who had failed prior LuPSMA treatment

Provided September 21, 2020, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may


vary materially; Amgen disclaims any duty to update.



EXAMPLES OF DEEP RESPONSES TO AMG 160


Patient 10112001002 Surgery, radiotherapy, docetaxel, **Prior Rx** enzalutamide, bicalutamide, and talazoparib Cohort 4 (0.09 mg with cycle 1 priming)

> PR by 3 Months PSMA PET/CT



Baseline

Week 12




Patient 10166004005


Prior Rx Surgery, docetaxel, enzalutamide, sipuleucel

Cohort 4 (0.09 mg with optimised cycle 1 priming)

Not RECIST evaluable **PSMA PET/CT**




Baseline



Patient	10166004006
Prior Rx	Radiotherapy, apalutamide, docetaxel, sipuleucel-T, radium-223
Cohort	5 (0.3 mg with optimised cycle 1 priming)

PR (u)* by 2.5 Months



Baseline Week 10 T01 Liver 40% reduction Segment VIII vs baseline **Rapid PSA Reduction** 2000 1800 1600 1400 Best PSA reduction: hg/L 1200 -75.5% 1000 PSA, 800 600 400 200 33 Screening Davs on Treatment

PET/CT = positron emission tomography-computed tomography; PR = partial response; PSA = prostate-specific antigen; PSMA = prostate-specific membrane antigen; RECIST = Response Evaluation Criteria in Solid Tumors; u = unconfirmed; * PR (u) response reported after 20 July, 2020 data cutoff Provided September 21, 2020, as part of an oral presentation and is

AMGEN

gualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

CONCLUSIONS


- AMG 160 had a manageable safety profile as monotherapy
 - CRS was reversible and manageable with priming doses and standard mitigations
 - No grade 5 TRAEs or treatment-related discontinuations
- In heavily pretreated patients, AMG 160 showed preliminary evidence of efficacy
 - Overall, 68.6% of patients showed any PSA decline across all monotherapy dose cohorts
 - 34.3% of patients showed ≥ PSA50 reduction
 - Among the 15 patients with measurable disease, 3 PR (2 confirmed) and 8 SD were observed
- 44.2% of patients remained on AMG 160 at the time of data analysis, with 6 (14.0%) patients continuing treatment for ≥ 6 months
- MTD has not been reached and dosing optimisation of AMG 160 continues as study nears RP2D; investigation of AMG 160 in combination with pembrolizumab is in progress

For more information, please contact Amgen Medical Information: medinfo@amgen.com

CRS = cytokine release syndrome; MTD = maximum tolerated dose; PR = partial response; PSA = prostate-specific antigen; PSA50 = PSA decrease of \geq 50%; RP2D = recommended phase 2 dose; SD = stable disease Provided September 21, 2020, as part of an oral presentation and is

vary materially; Amgen disclaims any duty to update.







AMG 160 DATA AT ESMO VIRTUAL CONGRESS 2020

SEPTEMBER 21, 2020

